Invivyd, Inc.

Equities

IVVD

US00534A1025

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:03:47 2024-04-25 pm EDT			5-day change	1st Jan Change
2.085 ^USD	-2.11%		-11.28%	-47.08%

Apr. 15	Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	CI
Apr. 12	Invivyd Names Jeremy Gowler as Interim CEO	MT

Adagio Therapeutics to Participate in Upcoming Investor Conferences

November 10, 2021 at 06:31 am EST

WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences:

Stifel 2021 Virtual Healthcare Conference: Management will participate in a fireside chat discussion on Tuesday, November 16, 2021, at 8:40 a.m. ET.
Jefferies 2021 Virtual London Healthcare Conference: Management will participate in a fireside chat discussion during the conference, being held November 16-19, 2021. The fireside chat will be available to registered participants on-demand between 8:00 a.m. GMT on November 18, 2021, and 5:00 p.m. GMT on November 19, 2021.
Evercore ISI 4th Annual HealthconX Conference: Management will participate in a fireside chat discussion on Wednesday, December 1, 2021, at 2:40 p.m. ET.

The webcasts will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Latest news about Invivyd, Inc.

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	Apr. 15	CI
Invivyd Names Jeremy Gowler as Interim CEO	Apr. 12	MT
Invivyd, Inc. Announces Executive Changes	Apr. 12	CI
Invivyd, Inc. Announces CEO Changes	Apr. 12	CI
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9	Apr. 05	MT
Transcript : Invivyd, Inc. - Special Call	Apr. 04
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours	Apr. 04	MT
Invivyd Sees Covid-19 Prevention Treatment Revenue of Up to $200 Million This Year	Apr. 04	DJ
Invivyd, Inc. Provides Earnings Guidance for the Year 2024	Apr. 04	CI
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Mar. 26	MT
Invivyd Clears Significant Hurdle After Pemgarda Authorization, Morgan Stanley Says	Mar. 26	MT
Top Premarket Gainers	Mar. 26	MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	Mar. 26	MT
North American Morning Briefing : Tech in Focus on Reports of China Restrictions	Mar. 25	DJ
Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval	Mar. 22	DJ
Transcript : Invivyd, Inc. - Special Call	Mar. 22
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt	Mar. 22	MT
Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults	Mar. 22	DJ
Invivyd, Inc. Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial	Mar. 22	CI
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA? (Formerly VYD222) for Pre-exposure Prophylaxis of COVID-19	Mar. 22	CI
HC Wainwright Raises Price Target on Invivyd to $15 From $5, Keeps Buy Rating	Jan. 18	MT

Chart Invivyd, Inc.

Duration

Period

More charts

Company Profile

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Companyâs proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Companyâs first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.13 USD

Average target price

9.375 USD

Spread / Average Target

+340.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INVIVYD, INC.	-47.08%	254M
VERTEX PHARMACEUTICALS INCORPORATED	-2.08%	104B
REGENERON PHARMACEUTICALS, INC.	+1.61%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.76%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-16.96%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.66%	13.98B
SAREPTA THERAPEUTICS, INC.	+33.26%	11.66B

Bio Therapeutic Drugs